ZGEN News and Press, The Generation Z ETF

2023-03-27 12:08:02 ET Closures of exchange traded funds have reached a pace in early 2023 that the industry hasn't seen since 2020. As market uncertainty grows, it seems that investors have become more selective in how they deploy capital, which has had an impact on certain thematic ET...

There is no faith in Palantir right now. Headline results were mixed at best. Expenses are on the rise, but cash flow is positive and the balance sheet is pristine. The pace of growth is clearly slowing, and that is a major issue for an earnings-light company. So, Pa...

Coursera’s recent second quarter earnings missed expectations. Management cut their revenue growth guidance by almost a quarter. After hours, shares cratered by as much as 40%. Enterprise growth is still solid, but the company has struggled to add new clients. I think C...

Palantir's Q1 earnings left something to be desired, though commercial expansion has been a strong positive. There are many global risks that could spike demand from governments. Palantir will report Q2 earnings in a few weeks, and our expectations have grown a bit more conservati...

Affirm reported a stronger than expected quarter in May, with revenue and GMV both coming in nicely above expectations. Guidance for Q4 was slightly disappointing, with revenue below consensus at the midpoint and adjusted operating loss widening. Valuation does not appear overly a...

Teladoc has failed to recover from the guidance shock in 1Q-22. Sales growth slowed at a scary pace in 1Q-22, suggesting that guidance risks have increased. Teladoc’s stock remains hopelessly overvalued. Teladoc Health, Inc. ( TDOC ) is experiencing a sign...

Teladoc is officially a value stock, trading at a price-to-book discount. Impairment losses dealt a big blow to investors. However, operating performance can't be doubted. The company is growing its market share in the telehealth space by acquiring hypergrowth companies that provi...

Teladoc is down 90% from its ATH and I sold my position at a 75% loss. In this article, I will discuss what went wrong. I missed a lot of red flags about Teladoc, like low insider ownership and bad capital allocation. I ignored several of my investing rules and wasn't objective. ...

Palantir’s shares have been trampled upon this year. The firm's government segment and recent contract win should stabilize Palantir as the economy likely heads into a recession. Palantir is cashed up and has no financial debt. For further details see: Palantir: A...

Short interest in Palantir dropped by nearly 19% in the last cycle. Palantir saw one of the highest short unwinding amongst its peer group. Palantir stock seems to be forming a bottom, and it may not have much downside potential from current levels. For further details see: ...